Antimicrobials · Extended-Spectrum Penicillins
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Piperacillin-tazobactam is a broad-spectrum combination antibiotic providing coverage against Pseudomonas aeruginosa, anaerobes, and Gram-negative bacilli.
The addition of tazobactam acts as a beta-lactamase inhibitor to prevent degradation of piperacillin by bacterial enzymes.
This agent is the empiric treatment of choice for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).
Piperacillin-tazobactam is frequently utilized for intra-abdominal infections due to its robust activity against Bacteroides fragilis.
Clinical use is associated with an increased risk of acute kidney injury (AKI), particularly when combined with vancomycin.
It is not effective against MRSA (methicillin-resistant Staphylococcus aureus) or atypical pathogens like Mycoplasma or Legionella.
Patients with a severe IgE-mediated allergy to penicillin should avoid this medication due to the risk of anaphylaxis.
Vignette unlocked
A 68-year-old male is admitted to the ICU for respiratory failure and is started on mechanical ventilation. On hospital day 4, he develops a fever of 102.4°F (39.1°C), purulent tracheal secretions, and leukocytosis. Chest X-ray reveals a new dense consolidation in the right lower lobe. His past medical history is significant for chronic kidney disease stage 3. The team decides to initiate broad-spectrum empiric antibiotic therapy.
Which of the following antibiotic regimens is most appropriate for the empiric treatment of this patient's condition?
Piperacillin-tazobactam plus Vancomycin
The patient has ventilator-associated pneumonia requiring coverage for Pseudomonas (Piperacillin-tazobactam) and MRSA (Vancomycin), though clinicians must monitor for the synergistic risk of AKI.
Full handout
High yield triage
Classification
Extended-spectrum penicillin combined with a beta-lactamase inhibitor.
Indications
Pseudomonas aeruginosa infections, hospital-acquired pneumonia, and intra-abdominal infections.
Mechanism of Action
Inhibits bacterial cell wall synthesis via penicillin-binding proteins; tazobactam prevents beta-lactamase degradation.
Side Effects
Diarrhea, rash, anaphylaxis, nephrotoxicity, and thrombocytopenia.
Contraindications / Monitoring
History of severe penicillin allergy. Monitor renal function and CBC.
Full handout
Mechanism of Action
Piperacillin binds to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. Tazobactam acts as a suicide inhibitor of beta-lactamases, protecting piperacillin from enzymatic hydrolysis. This synergy expands the spectrum to include gram-negative organisms and anaerobes that produce beta-lactamase.
Unique Properties
It is the broadest spectrum penicillin available, often referred to as an anti-pseudomonal penicillin. Unlike other penicillins, it provides robust coverage against Bacteroides fragilis and Pseudomonas aeruginosa.
Indications
Used empirically for hospital-acquired pneumonia and ventilator-associated pneumonia. It is a first-line agent for complicated intra-abdominal infections and febrile neutropenia (in combination with other agents). Also indicated for skin and soft tissue infections involving polymicrobial flora.
Pharmacokinetics
Excreted primarily via the kidneys; dosage adjustments are mandatory in renal impairment. It is not orally bioavailable and must be administered via intravenous infusion.
Side Effects & Adverse Events
Common effects include nausea and diarrhea. Anaphylaxis is a rare but life-threatening type I hypersensitivity reaction. Prolonged use may lead to thrombocytopenia or leukopenia. Clostridioides difficile-associated diarrhea is a significant risk due to broad-spectrum activity.
Contraindications
Absolute contraindication in patients with a history of IgE-mediated hypersensitivity (e.g., anaphylaxis, angioedema) to any penicillin. Use with extreme caution in patients with a history of cephalosporin allergy due to potential cross-reactivity.
Monitoring
Monitor serum creatinine and BUN to adjust dosing for renal clearance. Perform periodic CBC to screen for drug-induced neutropenia during prolonged therapy. Monitor for signs of C. difficile colitis.
Clinical Pearls
The classic board setup is a patient with sepsis or nosocomial infection requiring broad-spectrum coverage. Remember it is the drug of choice for Pseudomonas when combined with other agents. Do not use for MRSA coverage, as it lacks activity against this pathogen.